AT100 is a monoclonal antibody highly specific for phosphorylated Tau in Alzheimer paired helical filaments. Here we show that the epitope is generated by a complex sequence of sequential phosphorylation, first of Ser199, Ser202 and Thr205 (around the epitope of antibody AT8), next of Thr212 by glycogen synthase kinase (GSK)-3β (a proline-directed kinase), then of Ser214 by protein kinase A (PKA). Conversely, if Ser214 is phosphorylated first it protects Thr212 and the Ser-Pro motifs around the AT8 site against phosphorylation, and the AT100 epitope is not formed. The generation of the AT100 epitope requires a conformation of tau induced by polyanions such as heparin, RNA or poly(Glu), conditions which also favor the formation of paired helical filaments. The Alzheimer-like phosphorylation can be induced by brain extracts. In the extract, the kinases responsible for generating the AT100 epitope are GSK-3β and PKA, which can be inhibited by their specific inhibitors LiCl and R II , respectively. A cellular model displaying the reaction with AT100 is presented by Sf9 insect cells transfected with Tau. Knowledge of the events and kinases generating the AT100 epitope in cells might allow us to study the degeneration of the cytoskeleton in Alzheimer's disease.
appeared to be more complex, depended on more than one ki-centrifuged at 100 000 g for 10 min at 4°C. The supernatant was nase, and depended on a folded conformation. We show here used for the phosphorylation. The reaction was carried out in that the epitope can be generated by two kinases (GSK-3β and 40 mM Hepes, pH 7.2, 3 mM MgCl 2 , 5 mM EGTA, 2 mM ATP, PKA) in a sequential manner, affecting two nearby residues 10 µM okadaic acid und a cocktail of protease inhibitors. 1 µl (Thr212 and Ser214). It also depends on the prior phosphoryla-extract was added to 20 µl Tau solution (0.5 µg/µl) at 37°C for tion of (Ser or Thr)-Pro motifs around residue 200 (including 16 h. For phosphorylation experiments with the brain extract in the AT8 epitope). Thirdly, it requires a conformation of Tau that the presence of kinase inhibitors the brain extract was first incuis conducive to PHF formation and can be generated in vitro by bated with 10 mM, 20 mM or 50 mM LiCl (to inhibit GSK-3) polyanions such as heparin, RNA, or poly(Glu). The epitope can or R II subunit (to inhibit PKA) for 10 min at room temperature be generated by kinases present in the brain extract, and it occurs and then added to Tau protein. in certain cellular environments. Thes results offer the prospect Phosphorylation by different kinases. All phosphorylation of monitoring Alzheimer-like processes of degeneration in cell reactions were carried out at 37°C in 40 mM Hepes, pH 7.2, models.
3 mM MgCl 2, 5 mM EGTA, 2 mM ATP and a cocktail of protease inhibitors. For the simultaneous phosphorylation by two kinases the reaction was initiated by the addition of the kinases at the same time. For sequential phosphorylation the reaction was MATERIALS AND METHODS initiated with one kinase. After 1Ϫ16 h the second kinase was Monoclonal antibodies and kinases. Antibodies AT8, added. Aliquots of the reaction products were used for SDS/ AT180, AT270, and AT100 were obtained from Innogenetics PAGE and immunoblots. (Mercken et al., 1992) , monoclonal antibody 12E8 was from
Immunoblots. For immunoblot analysis, the proteins or pepAthena Neurosciences (Seubert et al., 1995) , monoclonal anti-tides were transferred to PVDF membranes (Millipore) and the body PHF-1 was a gift from P. Davies (Albert Einstein College, residual protein-binding sites were blocked with 5% milk in Bronx NY; , and Tau-1 was a gift from 10 mM Tris/HCl pH 7.2, 150 mM NaCl, 0.05% Tween 20. The L. Binder (Northwestern University, Chicago IL; Binder et al., blots were incubated for 1Ϫ2 h at room temperature with pri-1985) . For epitopes see Fig. 2 . As a control for total Tau we mary antibodies AT8 (dilution 1 :4000), AT100 (1 :500), AT180 used the polyclonal human Tau antibody from DAKO. Recombi-(1:1000), AT270 (1:4000), PHF-1 (1:500), and 12E8 (1 :4000). nant MAP kinase activator was prepared by K. Stamer, and The secondary antibody was labelled with horseradish peroxiCdk5 by K. Baumann. Insulin-stimulated protein kinase (ISPK ; dase. Bound antibody was detected by the enhanced chemilumialias MAP-kinase-activated protein kinase 1 or 90-kDa ribo-nescence System (Amersham). somal S6 kinase ; Sutherland et al., 1993) was a gift from P.
Phosphopeptide mapping. Mapping was performed Cohen (Dundee). PKA was from Promega and PKC from Boeh-following Boyle et al. (1991) . After phosphorylation reactions ringer Mannheim. The PKA regulatory subunit type II (R II ) was using [γ- 32 P]ATP, the kinase was removed by boiling the sample from Promega. in 0.5 M NaCl, 10 mM dithiothreitol and centrifugation. The Cloning and expression of recombinant constructs of heat-stable Tau was precipitated with trichloroacetic acid. CysteTau. Recombinant Tau constructs derived from the smallest hu-ine residues were oxidized by performic acid treatment. The proman Tau isoform, Tau23 (352 residues ; Goedert et al., 1989) , tein was digested overnight with trypsin (Promega, sequencing were expressed in pNG2 expression vector, a derivative of pET-3 grade) using two additons of enzyme in a ratio of 1:20 (by (Studier et al., 1990) as described by . The mass). Two-dimensional phosphopeptide mapping by thin-layer following point mutations of Tau23 were generated: Ser198→ electrophoresis/chromatography was performed on thin-layer Ala, Ser199→Ala, Thr205→Ala, Ser208→Ala, Ser210→Ala, cellulose plates (Macherey & Nagel). The identification of spots Thr212→Ala, Ser214→Ala and Thr217→Ala. The deletion mu-was described previously (Drewes et al., 1995; Illenberger et tants of Tau23 cDNA were prepared by cassette mutagenesis al. , 1996) . Ser214 was identified by peptide sequencing and by using the synthetic oligonucleotides as adapters for replacing the comparison with defined phosphorylated peptides. original sections of Tau23 cDNA sequence as described by Proteolysis. The proteins were phosphorylated as described Gustke et al. (1994) . The Tau23 constructs were expressed in above and stopped by boiling with 500 mM NaCl and 5 mM Escherichia coli BL21(DE3) (Studier et al., 1990) . The ex-dithiothreitol for 10 min. After centrifugation at 14 000 g for pressed proteins were purified from bacterial extracts by making 10 min, the heat-stable supernatant was precipitated with aceuse of the heat stability of the proteins and by FPLC Mono S tone. The dried pellets were diluted with 50 mM sodium phos-(Pharmacia) chromatography as described by Hagestedt et al. phate pH 8.0. The endoproteinase AspN (Boehringer Mann-(1989) .
heim) was added (1 :20 of Tau) at 37°C for 2Ϫ20 h. The final Preparation of biopsy Tau, fetal Tau and PHF tau. Brain concentration of Tau was 0.5 µg/µl. tissue was boiled in a microwave oven for 2 min and homogeImmobilization of peptides in the ProBlot membrane. nized with 5 ml 50 mM Pipes, pH 6.9, 0.5 M NaCl, 5 mM
The proteins were digested as described above. Tricine/SDS/ EDTA, 5 mM EGTA, 50 mM NaF, 1 mM Na 3 VO 3 , 5 mM dithio-PAGE was used to seperate peptides as described by Schägger threitol, 1 mM PhMeSO2F, 10 µM microcystin, and a cocktail of and von Jagow (1987) . For sequencing the peptides were other protease inhibitors. The homogenate was centrifuged for electrotransferred to ProBlot membranes (Applied Biosystems) 1 h at 40000 g. The supernatant was concentrated according to in 50 mM sodium borate pH 9, 20% methanol for 3 h at 1 mA/ the method of Wessel and Flügge (1984) and used for immucm 2 . noblotting. PHF Tau was preparated as described by Greenberg
Sequencing of peptides immobilised in the ProBlot memand Davies (1990) .
brane. After immobilizing the ProBlot membrane, it was stained Phosphorylation by brain kinase activity. Extracts from with Ponceau Red (Sigma). The membrane containing the pepmouse brain were prepared as described (Lichtenberg-Kraag et tides was cut out as a 3 mmϫ7 mm piece. After washing with al., 1992) by homogenizing the brain tissue in 50 mM Tris/HCl bidistilled water and drying, the sequence analysis was perpH 8.0, 5 mM EGTA, 2 mM dithiothreitol, 50 mM NaF, 1 mM formed using a 476A liquid-phase protein sequencer (Applied Na 3 VO 3 and a cocktail of protease inhibitors (leupeptin, aprotinin, pepstantinA at 10 µg/ml each and 1 mM PhMeSO 2 F) and Biosystems). Phosphoserine was identified by the formation of AT100. Human Tau40 (hTau40) is the largest isoform in human central except AT100 which appears to be the most specific antibody for Alznervous system (441 residues ; Goedert et al., 1989) . Domains are indiheimer Tau.
cated by shading (P1, P2 are basic and Pro-rich). The repeats are numbered R1ϪR4. The subdivision of domains follows that used by Gustke et al. (1994) . The human isoform Tau23 (htau23) is the smallest in human central nervous system (352 residues); it lacks the two inserts near the dithiothreitol adduct of dehydroalanine from serine phosthe N-terminus and repeat 2 (exons 2, 3 and 10; thin lines). The conphate prior to sequencing . indicated. The deletion constructs contain at least one of the P domains Pharmingen) and pVL1392-tau vector derivatives (2 µg), using (P2) and variable extensions on either side. a calcium phosphate precipitation method. Viruses released by the transfected cells were amplified and the plaque assay was performed for the titer determination. To produce the recombi-fore, antibodies that are almost exclusively reactive with Alznant Tau proteins the monolayer cultures of Sf9 cells were in-heimer Tau are of particular interest. One such example is fected with viral stocks at multiplicities of infectivity of 5Ϫ10. AT100 (Mercken et al., 1992; Fig. 1) . Samples of Alzheimer Tau proteins were purified from the harvested Sf9 cells by mak-Tau after autopsy, Tau from a non-Alzheimer human brain biing use of their heat stability and examined by SDS/PAGE and opsy, and fetal brain were stained with several antibodies against Western blot analysis. phosphorylated (Ser or Thr)-Pro motifs (AT8, AT180, AT270 and PHF-1). The Alzheimer sample showed the highest degree of phosphorylation. Most antibodies showed a weaker reaction RESULTS with fetal and biopsy Tau, but AT100 reacted exclusively with The AT100 epitope is highly specific for Tau from Alzheimer Alzheimer tissue, showing that this antibody is specific for the tissue. A number of antibody epitopes have been described that disease state. distinguish Alzheimer Tau from Tau in normal brain tissue and are thus of diagnostic value. Many of these depend on phosphor-The AT100 epitope contains phosphorylated Thr212 and Ser214. To determine the epitope we used a set of recombinant ylation, especially at Ser-Pro or Thr-Pro motifs, indicating an overactivity of proline-directed kinases or an underactivity of constructs of Tau expressed in E. coli, some of which are shown in Fig. 2 . On the basis of amino acid character, Tau can be subdithe corresponding phosphatases. While Alzheimer Tau shows an elevated phosphorylation (Ϸ8 P i /molecule; Ksiezak-Reding et vided into several domains . For the present work, the important ones are the repeat (R) domains ( Fig. 2 ) and al., 1992; Köpke et al., 1993) , non-Alzheimer tissue also shows some phosphorylation at similar sites. This is particular visible the extensions on either side, the basic regions P1 and P2, and the basic C-terminal tail. P1 and P2 form essentially one domain, in biopsy material or fetal tissue (Matsuo et al., 1994) . There- 1, unphosphorylated human Tau23. Lanes 2Ϫ8, Tau23, K17, K23, K25, With the aim of defining the epitope of AT100 more pre-K33, K35 and K43, respectively, after treatment with brain extract.
cisely we constructed a set of single or double point mutants where Ser or Thr residues were replaced by Ala (Fig. 2) , thus preventing their phosphorylation. Judging by the shift in the but they can be distinguished by chymotryptic cleavage after SDS gel, all point mutants were phosphorylated by the brain Tyr197, which also separates the C-terminal assembly fragment extract (Fig. 4 a) . Most constructs reacted with AT100, except of Tau and the N-terminal projection fragment (Steiner et al., when Thr212 or Ser214 were mutated into Ala, showing that 1990). The constructs shown here have P2 in common, with these two residues (when phosphorylated) are part of the AT100 variable extensions on either side, e.g. K17 is composed of P2 epitope. and the repeats, while K43 consists of P2 preceded by P1 and followed by the repeats.
The AT100 epitope requires sequential phosphorylation of Thr212 by GSK-3β and of Ser214 by PKA, phosphorylation To generate Alzheimer-like phosphorylated epitopes we used a kinase activity from brain extract; as shown earlier, normal around the AT8 epitope, and a PHF-like conformation of Tau. Several groups have shown that the proline-directed kimammalian brain tissue contains the protein kinases that can phosphorylate Tau efficiently provided that phosphatases are in-nases MAP kinase, GSK-3 (A or β) or Cdk5 can phosphorylate Ser-Pro or Thr-Pro motifs in Tau. Moreover Ser214 can be phoshibited, e.g. by okadaic acid (Lichtenberg-Kraag et al., 1992; . All the deletion constructs of Tau (Fig. 2) phorylated by several non-proline-directed kinases, such as PKA, PKC and ISPK (data not shown ; . were phosphorylated by the brain extract. This usually caused an increase of the apparent molecular mass in the SDS gel and These kinases were therefore considered candidates for generating the AT100 epitope. We used them singly or in combination a splitting into several bands, depending on the type and extent of phosphorylation (Butler and Shelanski, 1986; Fig. 3A) . How-to phosphorylate Tau, but the AT100 epitope did not appear.
Since the activity of kinases can be modified by polyanions, ever, the constructs differ in terms of their reaction with AT100 ( Fig. 3B) : human Tau23 and K35 (containing domains P1 and such as heparin, heparin was added to the solution, but again the AT100 epitope failed to form. We noted that Thr212 could be P2, the repeats, and the C-terminal tail) display a strong reac- The reaction with AT100 disappears when Thr212 or Ser214 are mutated Cdk5, GSK-3β, PKA no to Ala, indicating that these residues are mainly responsible for the Cdk5, PKA no AT100 epitope. The reaction also disappears for [Ala217]Tau, in contrast GSK-3β, PKA no to the phosphorylation with the brain extract (Fig. 4) , indicating that MAP kinase, PKA no Thr(P)217 is stimulatory for the AT100 epitope but not strictly part of MAP kinaseϩ GSK-3β, PKA no the epitope. The reaction was weak when Ser199, Ser202 or Thr205 Cdk5ϩ heparin, PKA no were mutated into Ala, showing that prior phosphorylation around the GSK-3βϩ heparin, PKA yes AT8 epitope was stimulatory for the AT100 epitope. (b)-Time course of MAP kinaseϩ heparin, PKA no sequential phosphorylation monitored by antibodies AT100 and A8. The GSK-3βϩ heparin, PKC no epitope of AT8 (Ser202 and Thr205) precedes that of AT100. (c) Induc-GSK-3βϩ heparin, ISPK no tion of the AT100 epitope on human Tau23 by different polyanions (heparin or tRNA). The protein was sequentially phosphorylated, first by GSK-3β in the presence of heparin (lane 2) or tRNA (lanes 3, 4), followed by PKA. Lane 1 shows the control without phosphorylation. Top, immunoblot with AT100, showing that heparin and tRNA induce the phosphorylated by GSK-3β independently of whether heparin epitope. The same effect was observed with poly(Glu) (data not shown).
was present, and likewise the phosphorylation of Ser214 by Bottom, immunoblot with AT8, showing that this epitope is generated PKA did not depend on heparin, indicating that the failure to independently of AT100.
induce the epitope was not due to a lack of activity of the kinases (data not shown). Tables 1 and 2 summarize the experiments with the various kinase combinations. They show that all of the kinases tested cating that these residues are neutral), and was weakened for mutants at residues 199, 202 and 205, suggesting that phosphorwere able to phosphorylate Tau (Table 1 ), yet almost none of the kinase combinations induced the AT100 epitope (Table 2 ). ylation at these sites might enhance the AT100 reaction (Fig. 5 a) . Since phosphorylated Ser202 and Thr205 constitute The key exception was to include polyanions [heparin, RNA and poly(Glu)], phosphorylate first with GSK-3β, then phosphory-the epitope of the antibody AT8, this antibody can be used as a sensor for phosphorylation around residue 200. The time depenlate with PKA. By contrast, application of the kinases simultaneously or in the reverse order (PKA first, GSK3-β second) did dence shown in the immunoblots (Fig. 5 b) illustrates that the AT8 epitope appears before the AT100 epitope, and the AT100 not generate the AT100 epitope. Fig. 5 a illustrates the sequential phosphorylation by GSK-3β reaction was observed only if the AT8 reaction was induced first. Thus, phosphorylation around residue 200 appears to be stimulaand PKA for the point mutants of Tau. As for the brain extract, the AT100 reaction was essentially absent for the mutants tory for the sequential phosphorylation of Thr212 and Ser214.
A special case is that of Thr217. The point mutant [Ala217]Tau [Ala212]Tau and [Ala214]Tau (indicating the epitope at these residues), was unaltered for mutants at 198, 208 and 210 (indi-contains the AT100 epitope after phosphorylation with the brain Fig. 7 . Mapping of AT100 epitope by proteolysis and antibody labeling. The human isoform Tau23 was phosphorylated as in Fig. 5 (first GSK-3β, then PKA) to generate the AT100 epitope, then cleaved with AspN protease and stained with antibodies AT100 (lanes 1 and 2), AT8 (lanes 3 and 4) and 12E8 (lane 5). Cleavage for up to 20 h leaves one major fragment (A; 21.5 kDa). Sequencing of the peptide by Edman degradation after blotting onto a poly(vinyl difluoride) membrane showed that the sequence was D146GKTKIAT. The molecular mass and the positions of Asp residues suggests that the peptide extends at least to Pro251 (preceding the potential cleavage site at Asp252) and thus prevents the phosphorylation at (Ser or Thr)-Pro residues around covers domains P1 and P2. This includes the epitope of AT8 (lanes 3 the AT8 and AT100 epitopes. (a) Blots with AT100 (lanes 1 and 2) and and 4). There is no significant cleavage at Asp193 after 20 h. 12E8 de-AT8 (lanes 3 and 4) show that the reaction occurs only when Tau is tects two main fragments (B and C), both starting with D252LKNVKSK phosphorylated initially with GSK-3β [with heparin (ϩHep) ; lanes 1 and in the first repeat. Fragment B probably extends to Lys344, fragment C 3]. The AT100 epitope is generated by subsequent phosphorylation with to Val313, neither of which includes the AT8 or AT100 epitopes. PKA (lane 1). Conversely, the initial phosphorylation with PKA (with or without heparin) prevents the formation of AT100 and AT8 epitopes (lanes 2 and 4). (b) Phosphopeptide map of Tau exposed to PKA (with heparin) for 15 min (left) shows that at this time Ser214 is phosphorytion. The conditions were chosen such that PKA phosphorylates lated almost exclusively, whereas extended phosphorylation (up to 15 h) essentially only one residue, as seen from the phosphopeptide leads to more than a dozen spots. map (Fig. 6 b) . The single spot seen after 15 min contains Ser(P)214 (as shown by isolation of the spot, sequencing, and comparison with defined marker peptides). In other words, phosphorylation of Ser214 by PKA blocks the subsequent phosphorextract (Fig. 4 b) , not with the purified kinases (Fig. 5a ). This can be explained by assuming that Thr(P)217 is stimulatory for ylation of Thr212 and around residue 200 by GSK-3β so that the AT100 and AT8 reactions can no longer take place. Thus, the phosphorylation of the AT100 epitope, but if it is absent (as in the [Ala217]Tau mutant) the stimulation can be achieved via there is an antagonistic relationship between Ser214 and the preceding (Ser or Thr)-Pro motifs. Phosphorylation of the (Ser or other kinases in the brain extract, acting on other unknown sites.
A further requirement for generating the AT100 epitope is Thr)-Pro motifs (by GSK-3β) is stimulatory for phosphorylation of Ser214 (by PKA), resulting in the AT100 epitope, but phosthe presence of polyanionic factors such as heparin, tRNA, or poly(Glu) (Fig. 5 c) . Such factors are known to modulate the ac-phorylation of Ser214 protects the neighboring sites against proline-directed phosphorylation. This effect occurs independently tivity of protein kinases so that phosphorylation reactions could be altered (Moreno et al., 1996) . In our experiments the phos-of polyanions.
To confirm the location of the AT100 epitope we combined phopeptide maps suggest that roughly the same sites are phosphorylated with or without polyanions (data not shown). We immunoblotting with proteolytic cleavage. One convenient cleavage site is behind Tyr197, generating essentially two fragtherefore prefer an alternative interpretation. Polyanionic substances are known to change the state of Tau and induce it to ments (projection and assembly fragments ; Steiner et al., 1990; Fig. 2 ). However, this cleavage could not be used because the self-assemble into PHF (Perez et al., 1996; Kampers et al., 1996) . These observations suggest that a PHF-phosphorylation around residues 200 by GSK-3β made Tau highly resistant to chymotryptic cleavage (analogous to observalike state is necessary to obtain the PHF-like epitope of AT100. The equivalence of different polyanions is illustrated in Fig. 5 c, tions with the protease calpain; Litersky and Johnson, 1992; Mercken et al., 1995) . We therefore chose AspN protease, which where heparin is compared with tRNA. The epitope of AT8 was formed even with low (or without) polyanions, but AT100 re-generated only a few interpretable fragments of Tau (Fig. 7) .
Extended cleavage generates one major fragment (21.5 kDa, quired a sufficient concentration of polyanions.
The reason why sequential phosphorylation is necessary for Fig. 7 ) starting at Asp146 as determined by sequencing from the blot. The molecular mass, the positions of Asp residues in Tau, the AT100 epitope is illustrated in Fig. 6 . If GSK-3β is applied before PKA the epitopes of AT100 and AT8 are generated and the absence of the 12E8 reaction suggests that the peptide extends to Pro251 and thus covers domains P1 and P2, including (Fig. 6 a) , but if PKA is applied first there is no antibody reac- and 4) compared with the unphosphorylated protein expressed in E. coli is not significantly influenced by LiCl or the R II subunit, suggesting that (lanes 1 and 3). (BϪD), immunoblots with antibodies Tau-1, AT8 and this epitope can be phosphorylated by other proline-directed kinases in AT100. All samples show a reaction with Tau-1, indicating that part of the brain extract, such as MAP kinase .
the protein is unphosphorylated around residue 200. The AT8 and AT100 reactions are seen only with Tau from the Sf9 cells.
the epitopes of AT8 and AT100. The AT100 epitope, once it is therefore searched for examples of AT100 reaction in cells. formed after phosphorylation, is retained in the P1ϪP2 domain, Fig. 9 illustrates an Sf9 insect cell transfected with Tau using even though its generation on these domains de novo is very the baculovirus vector. Sf9 Tau is phosphorylated, as seen from inefficient because it requires P2 and flanking regions on both the molecular-mass shift relative to Tau expressed in E. coli sides. Thus the underlying conformation appears to remain intact (Fig. 9 A) . The region around residue 200 is partly unphosphoryafter proteolysis. Labeling of the degradation products of Tau lated (thus reacting with antibody Tau-1), but in Sf9 Tau it is with another antibody, 12E8 (sensitive to phosphorylated Ser262 also partly phosphorylated (and therefore reacted with AT8). and Ser356, which are generated by PKA; Seubert et al., 1995) This pool of Tau is strongly phosphorylated at Thr212 and reveals a different set of fragments (Fig. 7 b) , both of which beSer214, generating the AT100 epitope (Fig. 9 D) . gin at Asp252 in the first repeat as determined by sequencing. Neither of these is recognized by AT8 and AT100, confirming that these epitopes lie in the P domain and do not require the DISCUSSION repeat domain, once they are formed.
In Alzheimer's disease Tau occurs in a hyperphosphorylated GSK-3β and PKA are the primary kinases responsible for form and in a particular state leading to the aggregation of PHF the AT100 epitope in the brain extract. The experiments de-(Grundke-Iqbal et al., 1986) . This has led to a strong interest in scribed above indicate that the AT100 epitope can be generated antibodies against Tau that are sensitive to its conformation or by the mixture of kinases present in the brain extract, or by the to its state of phosphorylation. Such antibodies are potentially sequential application of purified kinases GSK-3β and PKA. But useful as diagnostic tools, both for Alzheimer brain tissue and whether these two kinases were the active ingredients in the for the development of cellular or animal models. Some antibodbrain extract remained an open question. To narrow down the ies, such as Alz-50 and MC-1 (Carmel et al., 1996; Jicha et spectrum of kinases in the extract we used specific kinase inhibi-al., 1997), are sensitive to a folded conformation of Tau, while tors, LiCl for GSK-3β (Stambolic et al., 1996) , and the regula-phosphorylation dependent antibodies include the AT series tory subunit R II for PKA (Fig. 8) . Using the protocol for sequen- (Mercken et al., 1992) , the SMI series (Sternberger et al., 1985) , tial phosphorylation we found that increasing concentrations of PHF-1 , Tau-1 (Binder et al., 1985) and the inhibitors suppress the AT100 epitope (Fig. 8 a) . This argues others (Lee et al., 1991; Brion et al., 1993; Hasegawa et al., that GSK-3β and PKA (or similar isoforms) are the two respon-1993; Ishiguro et al., 1995) . Most of these antibodies have consible kinases. As a comparison, the AT8 epitope was not signifi-tiguous epitopes which are located on phosphorylatable secantly affected by either inhibitor, showing that Ser202 or quence motifs and can be deleted by point mutations. Some of Thr205 can be phosphorylated by other kinases in the extract as them depend on additional structural features, such as a folded well, probably MAP kinase or Cdk5 .
conformation (e.g. SMI34; Lichtenberg-Kraag et al., 1992) or a sequential phosphorylation, such as AT100. This antibody is of particular interest because it appears to be highly specific for The AT100 epitope occurs in cell models. Since AT100 is of diagnostic value in predicting an Alzheimer-like state of Tau it the Alzheimer state of Tau, in contrast to other antibodies with phospho-epitopes that also recognize a fraction of Tau in normal could be useful in studying the state of Tau in cell models. We factors (polyanions). The sequence of events leading to the AT100 epitope is shown in Fig. 10 . First, we need polyanionic cofactors, such as heparin, RNA or poly(Glu), probably to induce the conformation in Tau that is conducive to PHF formation (Perez et al., 1996; Kampers et al., 1996) . An alternative interpretation would be the known modulation of kinase activities by polyanions (for Tau and GSK-3; Moreno et al., 1996) . We prefer the conformation hypothesis because the time-course and the phosphorylation pattern of Tau at the critical residues are not changed by polyanions. Moreover, the importance of a particular conformation is shown by the observation that denaturants prevent the self-association of Tau into PHF. Second, we need stimulatory phosphorylation around residue 200 (Ser199, Ser202 and Thr205, including the AT8 epitope) which is achieved by GSK-3β. This appears to play a synergistic role in promoting the phosphorylation at the AT100 site. Likewise, Thr(P)217 appears to act in a stimulatory fashion. Third, Thr212 must be phosphorylated by GSK-3β, generating the first half of the epitope. Fourth, Ser214 must be phosphorylated by PKA, generating the full epitope.
The first two conditions are independent of each other, i.e. the PHF-like conformation can be induced independently of the AT8 epitope (Kampers et al., 1996) . The third step (Thr212 phosphorylation) occurs only when the first two conditions are met, and it is blocked if the fourth step (Ser214 phosphorylation) tope. Normal tau (a) adopts a PHF-like conformation that is inducible Dr L. I. Binder (Northwestern University) for Tau-1. Kinases were anisms for Tau (e.g. Singh et al., 1995) . It would therefore be kindly provided by Dr K. Baumann (Cdk5) and K. Stamer (MAP kinase tempting to relate the model of glycogen synthase phosphorylaactivator), and by Dr P. Cohen (Dundee University; ISPK). The cDNA tion to our current results ; however, we believe that a direct clone of GSK-3β was given generously by Dr J. Woodgett. Tau from comparison is not appropriate. In our case a 'priming' phosphor-fetal, adult biopsy, and Alzheimer tissue was prepared by Dr U. Gross ylation (of Ser214 by PKA) is inhibitory, not stimulatory. Stimu-and A. Thiemann. This work represents part of the doctoral thesis of latory phosphorylation (around the AT8 epitope) is achieved by Q. Z. GSK-3β itself (and not by another kinase), and this phosphorylation appears to occur independently of the AT100 epitope. The REFERENCES difference between the two targets of GSK-3, Tau and glycogen synthase, are due to their different structures. Tau largely lacks Archer, S. J., Vinson, V. K., Pollard, T. D. & Torchia, D. A. (1994) a compact folded structure and behaves like a highly soluble but Elucidation of the poly-L-proline binding site in Acanthamoeba profilin-I by NMR spectroscopy, FEBS Lett. 337, 145Ϫ151. natively denatured protein (Schweers et al., 1994) . The effect of Baumann, K., Mandelkow, E.-M., Biernat, J., Piwnica-Worms, H. & polyanions could be explained by a change in conformation, Abnormal Alzheimer-like phosphorylation of which may be locally restricted but leads to the formation of tau protein by cyclin-dependent kinases cdk2 and cdk5, FEBS Lett.
insoluble PHF (Perez et al., 1996; Kampers 336, 417Ϫ424. et al., 1996) . Similarly, the accumulation of phosphorylation Biernat, J., Mandelkow, E.-M., Schröter, C., Lichtenberg-Kraag, B., sites (which also have an anionic character) might induce a local
